Literature DB >> 18552863

Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded.

Roberto Cattaneo1, Tanner Miest, Elena V Shashkova, Michael A Barry.   

Abstract

Virotherapy is currently undergoing a renaissance, based on our improved understanding of virus biology and genetics and our better knowledge of many different types of cancer. Viruses can be reprogrammed into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Targeting introduces multiple layers of cancer specificity and improves safety and efficacy; arming occurs through the expression of prodrug convertases and cytokines; and coating with polymers and the sequential usage of different envelopes or capsids provides shielding from the host immune response. Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation.

Entities:  

Mesh：

Year:  2008        PMID： 18552863      PMCID： PMC3947522          DOI： 10.1038/nrmicro1927

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN： 1740-1526            Impact factor:   60.633


  115 in total

Review 1.  In vivo bioluminescence imaging for integrated studies of infection.

Authors:  Timothy C Doyle; Stacy M Burns; Christopher H Contag
Journal:  Cell Microbiol       Date:  2004-04       Impact factor: 3.715

2.  Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation.

Authors:  Patricia Devaux; Veronika von Messling; Warangkhana Songsungthong; Christoph Springfeld; Roberto Cattaneo
Journal:  Virology       Date:  2006-11-16       Impact factor: 3.616

3.  A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma.

Authors:  X-W Ren; M Liang; X Meng; X Ye; H Ma; Y Zhao; J Guo; N Cai; H-Z Chen; S-L Ye; F Hu
Journal:  Cancer Gene Ther       Date:  2006-02       Impact factor: 5.987

4.  Rescue and propagation of fully retargeted oncolytic measles viruses.

Authors:  Takafumi Nakamura; Kah-Whye Peng; Mary Harvey; Suzanne Greiner; Ian A J Lorimer; Charles D James; Stephen J Russell
Journal:  Nat Biotechnol       Date:  2005-01-30       Impact factor: 54.908

Review 5.  The plasminogen activation system in tumor growth, invasion, and metastasis.

Authors:  P A Andreasen; R Egelund; H H Petersen
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

Review 6.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

7.  Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.

Authors:  M Kuppuswamy; J F Spencer; K Doronin; A E Tollefson; W S M Wold; K Toth
Journal:  Gene Ther       Date:  2005-11       Impact factor: 5.250

8.  Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

Authors:  Xue Qing Lun; Hongyuan Zhou; Tommy Alain; Beichen Sun; Limei Wang; John W Barrett; Marianne M Stanford; Grant McFadden; John Bell; Donna L Senger; Peter A Forsyth
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

Review 9.  New developments in the virus therapy of cancer: a historical review.

Authors:  J Sinkovics; J Horvath
Journal:  Intervirology       Date:  1993       Impact factor: 1.763

10.  AdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy.

Authors:  Sander Idema; Martine L M Lamfers; Victor W van Beusechem; David P Noske; Stan Heukelom; Sharif Moeniralm; Winald R Gerritsen; W Peter Vandertop; Clemens M F Dirven
Journal:  J Gene Med       Date:  2007-12       Impact factor: 4.565
View more
  173 in total

Review 1.  Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.

Authors:  Guido Wollmann; Koray Ozduman; Anthony N van den Pol
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Oncolytic viruses: now interviewing for the all-star game.

Authors:  Richard Vile
Journal:  Mol Ther       Date:  2010-05       Impact factor: 11.454

3.  Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses.

Authors:  Amber Miller; Rebecca Nace; Camilo Ayala-Breton C; Michael Steele; Kent Bailey; Kah Whye Peng; Stephen J Russell
Journal:  Mol Ther       Date:  2015-12-09       Impact factor: 11.454

4.  Adenosine deaminase acting on RNA 1 (ADAR1) suppresses the induction of interferon by measles virus.

Authors:  Zhiqun Li; Kristina M Okonski; Charles E Samuel
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

5.  Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas.

Authors:  Wanlu Du; Ivan Seah; Oumaima Bougazzoul; GiHun Choi; Katrina Meeth; Marcus W Bosenberg; Hiroaki Wakimoto; David Fisher; Khalid Shah
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-14       Impact factor: 11.205

6.  DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.

Authors:  Katrin Friedrich; Jan Rh Hanauer; Steffen Prüfer; Robert C Münch; Iris Völker; Christodoulos Filippis; Christian Jost; Kay-Martin Hanschmann; Roberto Cattaneo; Kah-Whye Peng; Andreas Plückthun; Christian J Buchholz; Klaus Cichutek; Michael D Mühlebach
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

7.  Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

8.  Advances in the mechanisms of action of cancer-targeting oncolytic viruses.

Authors:  Cun-Zhi Lin; Gui-Ling Xiang; Xin-Hong Zhu; Lu-Lu Xiu; Jia-Xing Sun; Xiao-Yuan Zhang
Journal:  Oncol Lett       Date:  2018-01-19       Impact factor: 2.967

Review 9.  Self-assembled lipid nanomedicines for siRNA tumor targeting.

Authors:  Yu-Cheng Tseng; Leaf Huang
Journal:  J Biomed Nanotechnol       Date:  2009-08       Impact factor: 4.099

10.  Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.